163 related articles for article (PubMed ID: 37266655)
1. Can we rely on contrast-enhanced CT to identify pancreatic ductal adenocarcinoma? A population-based study in sensitivity and factors associated with false negatives.
LeBlanc M; Kang J; Costa AF
Eur Radiol; 2023 Nov; 33(11):7656-7664. PubMed ID: 37266655
[TBL] [Abstract][Full Text] [Related]
2. High-resolution pancreatic computed tomography for assessing pancreatic ductal adenocarcinoma resectability: a multicenter prospective study.
Lee DH; Ha HI; Jang JY; Lee JW; Choi JY; Bang S; Lee CH; Kim WB; Lee SS; Kim SC; Kang BK; Lee JM
Eur Radiol; 2023 Sep; 33(9):5965-5975. PubMed ID: 36988715
[TBL] [Abstract][Full Text] [Related]
3. Magnetic resonance with diffusion-weighted imaging improves assessment of focal liver lesions in patients with potentially resectable pancreatic cancer on CT.
Jeon SK; Lee JM; Joo I; Lee DH; Ahn SJ; Woo H; Lee MS; Jang JY; Han JK
Eur Radiol; 2018 Aug; 28(8):3484-3493. PubMed ID: 29352379
[TBL] [Abstract][Full Text] [Related]
4. Predictors of distant metastasis on exploration in patients with potentially resectable pancreatic cancer.
Liu X; Fu Y; Chen Q; Wu J; Gao W; Jiang K; Miao Y; Wei J
BMC Gastroenterol; 2018 Nov; 18(1):168. PubMed ID: 30400836
[TBL] [Abstract][Full Text] [Related]
5. Routine MRI With DWI Sequences to Detect Liver Metastases in Patients With Potentially Resectable Pancreatic Ductal Carcinoma and Normal Liver CT: A Prospective Multicenter Study.
Marion-Audibert AM; Vullierme MP; Ronot M; Mabrut JY; Sauvanet A; Zins M; Cuilleron M; Sa-Cunha A; Lévy P; Rode A
AJR Am J Roentgenol; 2018 Nov; 211(5):W217-W225. PubMed ID: 30240298
[TBL] [Abstract][Full Text] [Related]
6. CT-determined resectability of borderline resectable and unresectable pancreatic adenocarcinoma following FOLFIRINOX therapy.
Jang JK; Byun JH; Kang JH; Son JH; Kim JH; Lee SS; Kim HJ; Yoo C; Kim KP; Hong SM; Seo DW; Kim SC; Lee MG
Eur Radiol; 2021 Feb; 31(2):813-823. PubMed ID: 32845389
[TBL] [Abstract][Full Text] [Related]
7. Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection.
Marchegiani G; Todaro V; Boninsegna E; Negrelli R; Sureka B; Bonamini D; Salvia R; Manfredi R; Pozzi Mucelli R; Bassi C
Eur Radiol; 2018 Oct; 28(10):4265-4273. PubMed ID: 29679211
[TBL] [Abstract][Full Text] [Related]
8. Preoperative prediction of disease-free survival in pancreatic ductal adenocarcinoma patients after R0 resection using contrast-enhanced CT and CA19-9.
Li D; Peng Q; Wang L; Cai W; Liang M; Liu S; Ma X; Zhao X
Eur Radiol; 2024 Jan; 34(1):509-524. PubMed ID: 37507611
[TBL] [Abstract][Full Text] [Related]
9. Abbreviated Gadoxetic Acid-Enhanced MRI for the Detection of Liver Metastases in Patients With Potentially Resectable Pancreatic Ductal Adenocarcinoma.
Yamaguchi T; Sofue K; Ueshima E; Ueno Y; Tsujita Y; Yabe S; Shirakawa S; Toyama H; Hori M; Fukumoto T; Murakami T
J Magn Reson Imaging; 2022 Sep; 56(3):725-736. PubMed ID: 35005813
[TBL] [Abstract][Full Text] [Related]
10. Incremental Role of Pancreatic Magnetic Resonance Imaging after Staging Computed Tomography to Evaluate Patients with Pancreatic Ductal Adenocarcinoma.
Kim HJ; Park MS; Lee JY; Han K; Chung YE; Choi JY; Kim MJ; Kang CM
Cancer Res Treat; 2019 Jan; 51(1):24-33. PubMed ID: 29397657
[TBL] [Abstract][Full Text] [Related]
11. Assessment of Response to Neoadjuvant Therapy Using CT Texture Analysis in Patients With Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma.
Borhani AA; Dewan R; Furlan A; Seiser N; Zureikat AH; Singhi AD; Boone B; Bahary N; Hogg ME; Lotze M; Zeh HJ; Tublin ME
AJR Am J Roentgenol; 2020 Feb; 214(2):362-369. PubMed ID: 31799875
[No Abstract] [Full Text] [Related]
12. Radiomic feature reproducibility in contrast-enhanced CT of the pancreas is affected by variabilities in scan parameters and manual segmentation.
Yamashita R; Perrin T; Chakraborty J; Chou JF; Horvat N; Koszalka MA; Midya A; Gonen M; Allen P; Jarnagin WR; Simpson AL; Do RKG
Eur Radiol; 2020 Jan; 30(1):195-205. PubMed ID: 31392481
[TBL] [Abstract][Full Text] [Related]
13. Improving preoperative detection of synchronous liver metastases in pancreatic cancer with combined contrast-enhanced and diffusion-weighted MRI.
Riviere DM; van Geenen EJM; van der Kolk BM; Nagtegaal ID; Radema SA; van Laarhoven CJHM; Hermans JJ
Abdom Radiol (NY); 2019 May; 44(5):1756-1765. PubMed ID: 30659309
[TBL] [Abstract][Full Text] [Related]
14. Utility of Dark-Blood Dual-Energy CT Images for Predicting Vascular Involvement and R0 Resection in Patients With Pancreatic Cancer.
Si K; Wu H; Yang M; Guo Y; Zhang X; Ding C; Xue J; Han P; Li X
AJR Am J Roentgenol; 2023 Jun; 220(6):838-848. PubMed ID: 36541594
[No Abstract] [Full Text] [Related]
15. Vascular involvement and resectability of pancreatic ductal adenocarcinoma on contrast-enhanced MRI: comparison with pancreatic protocol CT.
Noda Y; Kawai N; Kaga T; Ishihara T; Hyodo F; Kato H; Kambadakone AR; Matsuo M
Abdom Radiol (NY); 2022 Aug; 47(8):2835-2844. PubMed ID: 35760922
[TBL] [Abstract][Full Text] [Related]
16. Adding Delayed Phase Images to Dual-Phase Contrast-Enhanced CT Increases Sensitivity for Small Pancreatic Ductal Adenocarcinoma.
Fukukura Y; Kumagae Y; Fujisaki Y; Yamagishi R; Nakamura S; Kamizono J; Nakajo M; Kamimura K; Nagano H; Takumi K; Yoshiura T
AJR Am J Roentgenol; 2021 Oct; 217(4):888-897. PubMed ID: 33759561
[No Abstract] [Full Text] [Related]
17. Validation of Prognostic Radiomic Features From Resectable Pancreatic Ductal Adenocarcinoma in Patients With Advanced Disease Undergoing Chemotherapy.
Salinas-Miranda E; Khalvati F; Namdar K; Deniffel D; Dong X; Abbas E; Wilson JM; O'Kane GM; Knox J; Gallinger S; Haider MA
Can Assoc Radiol J; 2021 Nov; 72(4):605-613. PubMed ID: 33151087
[TBL] [Abstract][Full Text] [Related]
18. Unresectable pancreatic ductal adenocarcinoma: Role of CT quantitative imaging biomarkers for predicting outcomes of patients treated with chemotherapy.
Cheng SH; Cheng YJ; Jin ZY; Xue HD
Eur J Radiol; 2019 Apr; 113():188-197. PubMed ID: 30927946
[TBL] [Abstract][Full Text] [Related]
19. Artificial intelligence for assessment of vascular involvement and tumor resectability on CT in patients with pancreatic cancer.
Bereska JI; Janssen BV; Nio CY; Kop MPM; Kazemier G; Busch OR; Struik F; Marquering HA; Stoker J; Besselink MG; Verpalen IM;
Eur Radiol Exp; 2024 Feb; 8(1):18. PubMed ID: 38342782
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic accuracy of laparoscopy following computed tomography (CT) scanning for assessing the resectability with curative intent in pancreatic and periampullary cancer.
Allen VB; Gurusamy KS; Takwoingi Y; Kalia A; Davidson BR
Cochrane Database Syst Rev; 2013 Nov; (11):CD009323. PubMed ID: 24272022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]